Literature DB >> 18055988

Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.

Silvia Giannini1, Anna Maria Mezzasoma, Mario Leone, Paolo Gresele.   

Abstract

BACKGROUND AND OBJECTIVES: von Willebrand's disease (VWD) is a heterogeneous bleeding disorder caused by quantitative or qualitative defects in von Willebrand factor (VWF). The diagnosis of VWD requires several laboratory tests. The aim of our study was to validate a flow cytometric test for the diagnosis of VWD and for monitoring the effects of desmopressin therapy. DESIGN AND METHODS: Flow cytometric analysis of ristocetin-induced VWF binding to platelets was performed in platelet-rich plasma (PRP) samples from patients with VWD and from control subjects and in samples of formalin-fixed platelets in the presence of plasma from patients or controls. In 12 VWD patients the test was conducted before and 1 hour after desmopressin infusion. Results were compared with VWF:Ag, VWF:RCo, VWF:CB, RIPA, PFA-100 and the skin bleeding time.
RESULTS: Ristocetin-induced VWF binding to platelets, evaluated by both flow cytometry-based assays, was significantly reduced in patients with type1, 2A and 2M VWD as compared with that in healthy subjects. Patients with type 2B VWD showed reduced binding of VWF to formalin-fixed platelets, but increased binding to autologous platelets in PRP, similar to RIPA. VWF binding to platelets assessed by both flow cytometric assays correlated significantly with VWF:Ag, VWF:RCo, VWF:CB, RIPA, PFA100 and bleeding time. VWF binding to platelets increased after desmopressin infusion. INTERPRETATION AND
CONCLUSIONS: The measurement of ristocetin-induced binding of VWF to platelets by flow cytometry is a sensitive, simple and rapid test for the diagnosis of VWD and for the monitoring of the effects of desmopressin therapy. The flow cytometric assay performed with autologous platelets is useful in the identification of type 2B VWD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055988     DOI: 10.3324/haematol.11313

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

1.  Enzymes that hydrolyze adenine nucleotides in platelets and polymorphisms in the alpha2 gene of integrin alpha2beta1 in patients with von Willebrand disease.

Authors:  Karen Freitas Santos; Vanessa Battisti; Maísa de Carvalho Corrêa; Thaís Rapachi Mann; Renata da Silva Pereira; Maria do Carmo Araújo; Alice Odete Brülê; Maria Rosa Chitolina Schetinger; Vera Maria Morsch
Journal:  Mol Cell Biochem       Date:  2010-03-25       Impact factor: 3.396

Review 2.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

3.  Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?

Authors:  Mariachiara Borghi; Giuseppe Guglielmini; Anna Maria Mezzasoma; Emanuela Falcinelli; Loredana Bury; Marco Malvestiti; Paolo Gresele
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

Review 4.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

5.  Diagnosis of platelet-type von Willebrand disease by flow cytometry.

Authors:  Silvia Giannini; Luca Cecchetti; Anna Maria Mezzasoma; Paolo Gresele
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

6.  Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families.

Authors:  Paolo Gresele; Emanuela Falcinelli; Silvia Giannini; Pio D'Adamo; Angela D'Eustacchio; Teresa Corazzi; Anna Maria Mezzasoma; Filomena Di Bari; Giuseppe Guglielmini; Luca Cecchetti; Patrizia Noris; Carlo L Balduini; Anna Savoia
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

7.  Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor.

Authors:  Lisa N van der Vorm; Li Li; Dana Huskens; Walid Chayouâ; Hilde Kelchtermans; Philip G de Groot; Mark Roest; Jasper A Remijn; Bas de Laat
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

8.  Mechanisms of thrombocytopenia in platelet-type von Willebrand disease.

Authors:  Loredana Bury; Alessandro Malara; Stefania Momi; Eleonora Petito; Alessandra Balduini; Paolo Gresele
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

9.  A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD.

Authors:  Loredana Bury; Emanuela Falcinelli; Haripriya Kuchi Bhotla; Anna Maria Mezzasoma; Giuseppe Guglielmini; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton; Paolo Gresele
Journal:  Blood Adv       Date:  2022-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.